Orchard Therapeutics plc Stock News

The U.S. Food and Drug Administration said on Monday it had approved UK-based Orchard Therapeutics' gene therapy for the treatment of children with a rare hereditary disease called metachromatic leuko

Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.

Orchard Therapeutics PLC Sponsored ADR (ORTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movi

Orchard Therapeutics, a small-cap gene therapy company, landed a premium-rich buyout offer from Kyowa Kirin today. With biotech valuations under pressure from high-interest rates, this deal may be the

Shares of Orchard Therapeutics (NASDAQ: ORTX) almost doubled this morning after Kyowa Kirin Co Ltd (TYO: 4151) announced plans of buying the gene therapy company. Details of Orchard-Kyowa definitive a

Shares of Orchard Therapeutics doubled in pre-market trading following the announcement that Japan-based pharmaceutical company Kyowa Kirin will acquire the gene therapy leader for approximately $477.

Orchard Therapeutics shares ORTX, -0.61% nearly doubled, to $15.79, after agreeing to be purchased by Japan's Kyowa Kirin 4151, -0.24% for at least $16 per share in cash, plus an additional contingent

Japanese pharmaceutical firm Kyowa Kirin said on Thursday it would acquire Britain-based biopharmaceutical company Orchard Therapeutics for $477.6 million, aiming to promote the development of new dru

Orchard Therapeutics PLC Sponsored ADR (ORTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't sugges

Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptance under Priority Review. The stock rises 16%.

Orchard Therapeutics plc is a London-based biotech company focused on developing gene therapies for rare diseases. The company's lead therapy, OTL-200, has received marketing authorization in Europe f

The consensus price target hints at a 365% upside potential for Orchard Therapeutics PLC Sponsored ADR (ORTX). While empirical research shows that this sought-after metric is hardly effective, an upwa

BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at Stifel's Ina

Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates.

BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the Guggen